ARMA BIO INC

ARMA Bio is a woman-owned biopharmaceutical company developing first-in-class small molecule therapeutics for metastatic castration-resistant prostate cancer (mCRPC). The company's lead program targets dual inhibition of full-length androgen receptor (AR-fl) and the AR-V7 splice variant — a key driver of resistance to standard-of-care therapies such as enzalutamide and abiraterone. Co-founded by researchers from Weill Cornell Medicine, ARMA Bio identified a molecular glue degrader from a screen of 170,000 small molecules that rapidly degrades both AR forms within hours. The company received NIH/NCI Fast Track SBIR designation and over $1.6M in Phase I and Phase II funding.